STOCK TITAN
  1. Home
  2. News
  3. APTO

Aptose Biosciences Inc - APTO STOCK NEWS

Welcome to our dedicated news page for Aptose Biosciences (Ticker: APTO), a resource for investors and traders seeking the latest updates and insights on Aptose Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aptose Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aptose Biosciences's position in the market.

News
Aptose Reports Results for the Fourth Quarter and Full Year 2023
Rhea-AI Summary
Aptose Biosciences Inc. announces financial results for the year ended December 31, 2023, highlighting positive clinical data for tuspetinib in AML and completion of Luxeptinib G3 formulation evaluation. The company also completed a public offering and private placement to strengthen its financial position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
earnings
-
News
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
Rhea-AI Summary
Aptose Biosciences Inc. will report financial results for Q4 and year-end 2023, along with a corporate update on March 26, 2024. The company focuses on developing oral targeted agents for hematologic malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
Rhea-AI Summary
Aptose Biosciences Inc. announced the closing of a public offering and private placement, raising approximately $13.7 million in total gross proceeds. The company sold 5,649,122 common shares and warrants at a combined offering price of US $1.71 per share. The private placement with Hanmi Pharmaceutical, Inc. resulted in the purchase of each common share at a price of US $1.90, representing an 11% premium over the price of the common shares issued as part of the public offering. The company intends to use the net proceeds to support clinical trials for tuspetinib, support the manufacture of tuspetinib clinical supplies, and for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
offering
News
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
Rhea-AI Summary
Aptose Biosciences Inc. has announced the pricing of an underwritten public offering of 4,912,280 common shares at a public offering price of US $1.71 per share, with an expected gross proceeds of approximately US $8.4 million. Additionally, a concurrent $4 million private placement of common shares with Hanmi Pharmaceutical, Inc. has been priced, representing ownership of 19.97% of the outstanding common shares of the company following the private placement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
offering
-
News
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
Rhea-AI Summary
Aptose Biosciences Inc. (APTO) reports promising data from the APTIVATE International Phase 1/2 Study of Tuspetinib (TUS) in Relapsed/Refractory AML Patients. TUS as a single agent and TUS/VEN combination demonstrate favorable safety and tolerability. TUS/VEN combination achieves a 25% complete response rate among all-comers, including a 20% CRc in wildtype AML. Total enrollment of patients receiving TUS or TUS/VEN is now over 160.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
Rhea-AI Summary
Aptose Biosciences Inc. (APTO) appoints Fletcher Payne as Chief Business Officer and Senior Vice President, Chief Financial Officer, bringing over 25 years of healthcare experience and overseeing business transactions totaling more than $3.7 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.02%
Tags
management
News
Aptose Reports Results for the Third Quarter 2023
Rhea-AI Summary
Aptose Biosciences Inc. (APTO) announces promising results for tuspetinib (TUS) in the treatment of relapsed/refractory AML, including a 48% overall response rate in heavily pre-treated patients and a favorable safety profile. The company also presented data demonstrating TUS's ability to target venetoclax (VEN) resistance mechanisms at the European School of Haematology conference. The clinical data for tuspetinib has been selected for oral presentation at the 65th American Society of Hematology Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.38%
Tags
earnings
-
News
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
Rhea-AI Summary
Aptose Biosciences Inc. announced that clinical data for tuspetinib has been selected for oral presentation at the 65th American Society of Hematology Annual Meeting. The presentation will include safety and efficacy data from Aptose's ongoing APTIVATE trial of tuspetinib in relapsed/refractory acute myeloid leukemia patients. The presentation will take place on December 9, 2023, in San Diego, CA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
clinical trial
-
News
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
Rhea-AI Summary
Aptose Biosciences released highlights from a clinical update event featuring its lead compound tuspetinib (TUS). TUS is a precision targeted kinase inhibitor that suppresses select kinases driving the proliferation of acute myeloid leukemia (AML). The combination of TUS with venetoclax (VEN) has shown promising results in difficult-to-treat VEN failure AML patients, with a 44% overall response rate (ORR). TUS directly targets VEN resistance mechanisms, making it a potential treatment option for VEN failure patients. The safety profile of TUS and TUS/VEN combination remains favorable. The company plans to initiate further studies to evaluate the efficacy and duration of response of TUS/VEN in AML patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.52%
Tags
none
News
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
Rhea-AI Summary
Aptose Biosciences will report financial results for Q3 2023 on November 9th and provide a corporate update. Analysts can pre-register for the Q&A session and access the audio webcast through the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.3%
Tags
conferences earnings
Stock APTO logo
Aptose Biosciences Inc

Nasdaq:APTO

APTO Rankings

#5122 Ranked by Market Cap
#8 Ranked by Stock Gains
N/A Ranked by Dividends

APTO Stock Data

20.27M
12.52M
19.71%
7.63%
0.54%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Canada
North York

About APTO

aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt